NeuroSense Therapeutics Signs Binding Term Sheet With Global Pharma Partner To Advance PrimeC For ALS; Includes Upfront Payment, Phase 3 Funding, Milestone Payments, And Double-Digit Royalties; Definitive Agreement Expected Q1 2025
Author: Benzinga Newsdesk | December 23, 2024 09:06am